Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.

about

Chronic myelomonocytic leukemia with central nervous system involvement.

P2860

Q50095677-1CBB2660-5CA5-4183-9F2E-F9083C214969

P2860

Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.

Item

http://www.wikidata.org/entity/Q38603384

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Allogeneic hematopoietic stem ...... ronic myelomonocytic leukemia.

@en

type

Item

label

Allogeneic hematopoietic stem ...... ronic myelomonocytic leukemia.

@en

prefLabel

Allogeneic hematopoietic stem ...... ronic myelomonocytic leukemia.

@en

P1476

Allogeneic hematopoietic stem ...... ronic myelomonocytic leukemia.

@en

P2093

Natasha Kekre

http://www.w3.org/2001/XMLSchema#string

Vincent T Ho

http://www.w3.org/2001/XMLSchema#string

P2860

The World Health Organization (WHO) classification of the myeloid neoplasms

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

Proposals for the classification of the myelodysplastic syndromes

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT

P304

123-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24215

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26453238

http://www.w3.org/2001/XMLSchema#string

Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.

about

P2860

P2860

Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698